CME’s new swap future uses Goldman Sachs patent

A businessman with a light-bulb head representing an idea

CME Group's planned new swap futures product is based on a patent owned by and licensed from Goldman Sachs – a deal some market participants see as an attempt by the investment bank to hedge its bets, as over-the-counter products face a tougher regulatory regime.

Goldman Sachs is one of four dealer market-makers for the product, which was announced by CME on September 18. The others are Citi, Credit Suisse and Morgan Stanley. The exchange could be paying Goldman Sachs as much as 15–20% of the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: